Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan-Feb;7(1-2 Suppl 1):S3.
doi: 10.5489/cuaj.229.

Metastatic castration-resistant prostate cancer: The emerging continuum of care

Fred Saad  1
Affiliations

Metastatic castration-resistant prostate cancer: The emerging continuum of care

Fred Saad. Can Urol Assoc J. 2013 Jan-Feb.
No abstract available

PubMed Disclaimer

References

    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. doi: 10.1056/NEJMoa040720. - DOI - PubMed
    1. Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4:380–4. doi: 10.5489/cuaj.10167. - DOI - PMC - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. doi: 10.1016/S0140-6736(10)61389-X. - DOI - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi: 10.1056/NEJMoa1014618. - DOI - PMC - PubMed
    1. Saad F, Asselah J. Chemotherapy for prostate cancer: clinical practice in Canada. Can Urol Assoc J. 2013;7:S5–S10. doi: 10.5489/cuaj.12284. - DOI - PMC - PubMed

LinkOut - more resources